[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)


Description

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study. This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled). The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study. The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current sta

Trial Eligibility

Key Inclusion Criteria: 1. Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV 1. For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL 2. For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5 3. For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5 2. Have measurable disease on cross sectional imaging documented by diagnostic computed tomography \[CT\], or magnetic resonance imaging \[MRI\] imaging, as described in the protocol 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 4. Adequate bone marrow and hepatic function. Key Exclusion Criteria: 1. Participants with central nervous system lymphoma or leptomeningeal lymphoma 2. Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma 3. Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma 4. Recent major surgery and history or organ transplantation 5. A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol. Note: Other protocol-defined Inclusion/Exclusion criteria apply

Study Info

Organization

Regeneron Pharmaceuticals


Primary Outcome

Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy


Outcome Timeframe Up to 35 days

NCTID NCT06097364

Phases PHASE3

Primary Purpose TREATMENT

Start Date 2023-11-14

Completion Date 2029-07-29

Enrollment Target 733

Interventions

DRUG Odronextamab

DRUG Rituximab

DRUG Cyclophosphamide

DRUG Doxorubicin

DRUG Vincristine

DRUG Prednisone/Prenisolone

Locations Recruiting

Investigative Clinical Research of Indiana

United States, Indiana, Noblesville


University of Kentucky

United States, Kentucky, Lexington


Henry Ford Hospital

United States, Michigan, Detroit


Cancer and Hematology Centers of Western Michigan

United States, Michigan, Grand Rapids


Clinical Research Alliance, Inc.

United States, New York, Westbury


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Hodgkin Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.